MedTrace Logo

Pharmacokinetic Interaction Between Midazolam and ID-082 in Healthy Subjects

NCT03363984 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-06-27

No results posted yet for this study

Summary

A clinical study in healthy male subjects to investigate whether the administration of ID-082 can affect the fate in the body (amount and time of presence in the blood) of midazolam.

Conditions

  • Healthy

Interventions

DRUG

Midazolam

Single oral administration of 2 mg midazolam under fasted conditions/outside of meal times

DRUG

ID-082

Administration of ID-082 under fasted conditions/outside of meal times

Sponsors & Collaborators

  • Idorsia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Fabienne Le Gac · Idorsia Pharmaceuticals Ltd.

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-27
Primary Completion
2017-12-19
Completion
2017-12-19

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03363984 on ClinicalTrials.gov